



Neuland Laboratories Limited
11th Floor (5th Office Level),
Phoenix IVY Building,
Plot No.573A-III, Road No.82,
Jubilee Hills, Hyderabad - 500033,
Telangana, India.

Tel: 040 67611600 / 67611700
Email: neuland@neulandlabs.com
www.neulandlabs.com

July 13, 2023

To
BSE Limited
Phiroze Jeejeebhoy Towers, 25th Floor,
Dalal Street, Mumbai - 400 001

The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANLAB; Series: EQ

Ref: Our letter dated May 26, 2023 on United States Food and Drug Administration (U.S.FDA) inspection at our Unit 3 manufacturing facility, located at Gaddapotharam village, Jinnaram, Sangareddy District

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We wish to inform that U.S.FDA has issued an Establishment Inspection Report (EIR) against the Inspection conducted at our Unit 3 manufacturing facility, located at Gaddapotharam village, Jinnaram, Sangareddy District, from 22nd to 26th of May 2023.

The U.S.FDA has concluded that this inspection is “closed”.

This is for your information and records.

Thanking you,

Yours Sincerely,
For Neuland Laboratories Limited

Sarada Bhamidipati
Company Secretary